The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus

C. Reasner, L. Olansky, T. L. Seck, D. E. Williams-Herman, M. Chen, L. Terranella, A. O. Johnson-Levonas, K. D. Kaufman, B. J. Goldstein

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Aims: This study was conducted to compare the glycaemic efficacy and safety of initial combination therapy with the fixed-dose combination of sitagliptin and metformin versus metformin monotherapy in drug-naive patients with type 2 diabetes. Methods: This double-blind study (18-week Phase A and 26-week Phase B) randomized 1250 drug-naÏve patients with type 2 diabetes [mean baseline haemoglobin A1c (HbA1c) 9.9%] to sitagliptin/metformin 50/500 mg bid or metformin 500 mg bid (uptitrated over 4 weeks to achieve maximum doses of sitagliptin/metformin 50/1000 mg bid or metformin 1000 bid). Results of the primary efficacy endpoint (mean HbA1c reductions from baseline at the end of Phase A) are reported herein. Results: At week 18, mean change from baseline HbA1c was -2.4% for sitagliptin/metformin FDC and -1.8% for metformin monotherapy (p < 0.001); more patients treated with sitagliptin/metformin FDC had an HbA1c value <7% (p < 0.001) versus metformin monotherapy. Changes in fasting plasma glucose were significantly greater with sitagliptin/metformin FDC (-3.8 mmol/l) versus metformin monotherapy (-3.0 mmol/l; p < 0.001). Homeostasis model assessment of β-cell function (HOMA-β) and fasting proinsulin/insulin ratio were significantly improved with sitagliptin/metformin FDC versus metformin monotherapy. Baseline body weight was reduced by 1.6 kg in each group. Both treatments were generally well tolerated with a low and similar incidence of hypoglycaemia. Abdominal pain (1.1 and 3.9%; p = 0.002) and diarrhoea (12.0 and 16.6%; p = 0.021) occurred significantly less with sitagliptin/metformin FDC versus metformin monotherapy; the incidence of nausea and vomiting was similar in both groups. Conclusion: Compared with metformin monotherapy, initial treatment with sitagliptin/metformin FDC provided superior glycaemic improvement with a similar degree of weight loss and lower incidences of abdominal pain and diarrhoea.

Original languageEnglish (US)
Pages (from-to)644-652
Number of pages9
JournalDiabetes, Obesity and Metabolism
Volume13
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint

Metformin
Type 2 Diabetes Mellitus
Therapeutics
Hemoglobins
Sitagliptin Phosphate
Abdominal Pain
Diarrhea
Fasting
Incidence
Proinsulin

Keywords

  • Diabetes
  • GIP
  • GLP-1
  • Metformin
  • Sitagliptin
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. / Reasner, C.; Olansky, L.; Seck, T. L.; Williams-Herman, D. E.; Chen, M.; Terranella, L.; Johnson-Levonas, A. O.; Kaufman, K. D.; Goldstein, B. J.

In: Diabetes, Obesity and Metabolism, Vol. 13, No. 7, 07.2011, p. 644-652.

Research output: Contribution to journalArticle

Reasner, C, Olansky, L, Seck, TL, Williams-Herman, DE, Chen, M, Terranella, L, Johnson-Levonas, AO, Kaufman, KD & Goldstein, BJ 2011, 'The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus', Diabetes, Obesity and Metabolism, vol. 13, no. 7, pp. 644-652. https://doi.org/10.1111/j.1463-1326.2011.01390.x
Reasner, C. ; Olansky, L. ; Seck, T. L. ; Williams-Herman, D. E. ; Chen, M. ; Terranella, L. ; Johnson-Levonas, A. O. ; Kaufman, K. D. ; Goldstein, B. J. / The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. In: Diabetes, Obesity and Metabolism. 2011 ; Vol. 13, No. 7. pp. 644-652.
@article{b90a28f2cfe447e19ff8f261cc0c734a,
title = "The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus",
abstract = "Aims: This study was conducted to compare the glycaemic efficacy and safety of initial combination therapy with the fixed-dose combination of sitagliptin and metformin versus metformin monotherapy in drug-naive patients with type 2 diabetes. Methods: This double-blind study (18-week Phase A and 26-week Phase B) randomized 1250 drug-na{\"I}ve patients with type 2 diabetes [mean baseline haemoglobin A1c (HbA1c) 9.9{\%}] to sitagliptin/metformin 50/500 mg bid or metformin 500 mg bid (uptitrated over 4 weeks to achieve maximum doses of sitagliptin/metformin 50/1000 mg bid or metformin 1000 bid). Results of the primary efficacy endpoint (mean HbA1c reductions from baseline at the end of Phase A) are reported herein. Results: At week 18, mean change from baseline HbA1c was -2.4{\%} for sitagliptin/metformin FDC and -1.8{\%} for metformin monotherapy (p < 0.001); more patients treated with sitagliptin/metformin FDC had an HbA1c value <7{\%} (p < 0.001) versus metformin monotherapy. Changes in fasting plasma glucose were significantly greater with sitagliptin/metformin FDC (-3.8 mmol/l) versus metformin monotherapy (-3.0 mmol/l; p < 0.001). Homeostasis model assessment of β-cell function (HOMA-β) and fasting proinsulin/insulin ratio were significantly improved with sitagliptin/metformin FDC versus metformin monotherapy. Baseline body weight was reduced by 1.6 kg in each group. Both treatments were generally well tolerated with a low and similar incidence of hypoglycaemia. Abdominal pain (1.1 and 3.9{\%}; p = 0.002) and diarrhoea (12.0 and 16.6{\%}; p = 0.021) occurred significantly less with sitagliptin/metformin FDC versus metformin monotherapy; the incidence of nausea and vomiting was similar in both groups. Conclusion: Compared with metformin monotherapy, initial treatment with sitagliptin/metformin FDC provided superior glycaemic improvement with a similar degree of weight loss and lower incidences of abdominal pain and diarrhoea.",
keywords = "Diabetes, GIP, GLP-1, Metformin, Sitagliptin, Type 2 diabetes",
author = "C. Reasner and L. Olansky and Seck, {T. L.} and Williams-Herman, {D. E.} and M. Chen and L. Terranella and Johnson-Levonas, {A. O.} and Kaufman, {K. D.} and Goldstein, {B. J.}",
year = "2011",
month = "7",
doi = "10.1111/j.1463-1326.2011.01390.x",
language = "English (US)",
volume = "13",
pages = "644--652",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus

AU - Reasner, C.

AU - Olansky, L.

AU - Seck, T. L.

AU - Williams-Herman, D. E.

AU - Chen, M.

AU - Terranella, L.

AU - Johnson-Levonas, A. O.

AU - Kaufman, K. D.

AU - Goldstein, B. J.

PY - 2011/7

Y1 - 2011/7

N2 - Aims: This study was conducted to compare the glycaemic efficacy and safety of initial combination therapy with the fixed-dose combination of sitagliptin and metformin versus metformin monotherapy in drug-naive patients with type 2 diabetes. Methods: This double-blind study (18-week Phase A and 26-week Phase B) randomized 1250 drug-naÏve patients with type 2 diabetes [mean baseline haemoglobin A1c (HbA1c) 9.9%] to sitagliptin/metformin 50/500 mg bid or metformin 500 mg bid (uptitrated over 4 weeks to achieve maximum doses of sitagliptin/metformin 50/1000 mg bid or metformin 1000 bid). Results of the primary efficacy endpoint (mean HbA1c reductions from baseline at the end of Phase A) are reported herein. Results: At week 18, mean change from baseline HbA1c was -2.4% for sitagliptin/metformin FDC and -1.8% for metformin monotherapy (p < 0.001); more patients treated with sitagliptin/metformin FDC had an HbA1c value <7% (p < 0.001) versus metformin monotherapy. Changes in fasting plasma glucose were significantly greater with sitagliptin/metformin FDC (-3.8 mmol/l) versus metformin monotherapy (-3.0 mmol/l; p < 0.001). Homeostasis model assessment of β-cell function (HOMA-β) and fasting proinsulin/insulin ratio were significantly improved with sitagliptin/metformin FDC versus metformin monotherapy. Baseline body weight was reduced by 1.6 kg in each group. Both treatments were generally well tolerated with a low and similar incidence of hypoglycaemia. Abdominal pain (1.1 and 3.9%; p = 0.002) and diarrhoea (12.0 and 16.6%; p = 0.021) occurred significantly less with sitagliptin/metformin FDC versus metformin monotherapy; the incidence of nausea and vomiting was similar in both groups. Conclusion: Compared with metformin monotherapy, initial treatment with sitagliptin/metformin FDC provided superior glycaemic improvement with a similar degree of weight loss and lower incidences of abdominal pain and diarrhoea.

AB - Aims: This study was conducted to compare the glycaemic efficacy and safety of initial combination therapy with the fixed-dose combination of sitagliptin and metformin versus metformin monotherapy in drug-naive patients with type 2 diabetes. Methods: This double-blind study (18-week Phase A and 26-week Phase B) randomized 1250 drug-naÏve patients with type 2 diabetes [mean baseline haemoglobin A1c (HbA1c) 9.9%] to sitagliptin/metformin 50/500 mg bid or metformin 500 mg bid (uptitrated over 4 weeks to achieve maximum doses of sitagliptin/metformin 50/1000 mg bid or metformin 1000 bid). Results of the primary efficacy endpoint (mean HbA1c reductions from baseline at the end of Phase A) are reported herein. Results: At week 18, mean change from baseline HbA1c was -2.4% for sitagliptin/metformin FDC and -1.8% for metformin monotherapy (p < 0.001); more patients treated with sitagliptin/metformin FDC had an HbA1c value <7% (p < 0.001) versus metformin monotherapy. Changes in fasting plasma glucose were significantly greater with sitagliptin/metformin FDC (-3.8 mmol/l) versus metformin monotherapy (-3.0 mmol/l; p < 0.001). Homeostasis model assessment of β-cell function (HOMA-β) and fasting proinsulin/insulin ratio were significantly improved with sitagliptin/metformin FDC versus metformin monotherapy. Baseline body weight was reduced by 1.6 kg in each group. Both treatments were generally well tolerated with a low and similar incidence of hypoglycaemia. Abdominal pain (1.1 and 3.9%; p = 0.002) and diarrhoea (12.0 and 16.6%; p = 0.021) occurred significantly less with sitagliptin/metformin FDC versus metformin monotherapy; the incidence of nausea and vomiting was similar in both groups. Conclusion: Compared with metformin monotherapy, initial treatment with sitagliptin/metformin FDC provided superior glycaemic improvement with a similar degree of weight loss and lower incidences of abdominal pain and diarrhoea.

KW - Diabetes

KW - GIP

KW - GLP-1

KW - Metformin

KW - Sitagliptin

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=79956315355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956315355&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1326.2011.01390.x

DO - 10.1111/j.1463-1326.2011.01390.x

M3 - Article

VL - 13

SP - 644

EP - 652

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 7

ER -